Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Dehydrocrenatidine Is a Novel Janus Kinase Inhibitor

Jing Zhang, Ning Zhu, Yuping Du, Qifeng Bai, Xing Chen, Jing Nan, Xiaodong Qin, Xinxin Zhang, Jianwen Hou, Qin Wang and Jinbo Yang
Molecular Pharmacology April 2015, 87 (4) 572-581; DOI: https://doi.org/10.1124/mol.114.095208
Jing Zhang
Schools of Life Sciences and Basic Medical Sciences, Lanzhou University, Lanzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ning Zhu
Schools of Life Sciences and Basic Medical Sciences, Lanzhou University, Lanzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuping Du
Schools of Life Sciences and Basic Medical Sciences, Lanzhou University, Lanzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qifeng Bai
Schools of Life Sciences and Basic Medical Sciences, Lanzhou University, Lanzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xing Chen
Schools of Life Sciences and Basic Medical Sciences, Lanzhou University, Lanzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jing Nan
Schools of Life Sciences and Basic Medical Sciences, Lanzhou University, Lanzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaodong Qin
Schools of Life Sciences and Basic Medical Sciences, Lanzhou University, Lanzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xinxin Zhang
Schools of Life Sciences and Basic Medical Sciences, Lanzhou University, Lanzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jianwen Hou
Schools of Life Sciences and Basic Medical Sciences, Lanzhou University, Lanzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qin Wang
Schools of Life Sciences and Basic Medical Sciences, Lanzhou University, Lanzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jinbo Yang
Schools of Life Sciences and Basic Medical Sciences, Lanzhou University, Lanzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    The electrostatic potentials of receptor and ligands. (A) The electrostatic potentials of AG490 and the pocket of JAK2. (B) The electrostatic potentials of dehydrocrenatidine and the pocket of JAK2. Dehydrocrenatidine can insert into the deeper position of JAK2 domain according to an analysis of molecular shape and electrostatic potential.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Dehydrocrenatidine inhibited STAT3-hyperactivated cancer cell survival and STAT3 phosphorylation without affecting P65 and Akt phosphorylation. hTERT-BJ, DU145, MDA-MB-468, and MCF 10A cells were treated with (A) dehydrocrenatidine, (B) AG490, (C) AZD1480, and (D) staurosporine at indicated concentrations for 48 hours, and cell viability was measured by MTT assay. (E) DU145 and MDA-MB-468 cells were treated with DMSO, dehydrocrenatidine (10 μM), Ly294002 (50 mM), and TPCA-1 (1 μM) for 2 hours and Western blotted.

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    Dehydrocrenatidine inhibited STAT3 phosphorylation in DU145 and MDA-MB-468 cells in a dose- and time-dependent manner. (A) DU145 and MDA-MB-468 cells were treated with indicated concentrations of dehydrocrenatidine for 2 hours, and cell lysates were blotted by indicated antibodies. DMSO was used as control. p-STAT3/STAT3 relative density was measured by Image J, and IC50 was calculated by SPSS software. (B) DU145 and MDA-MB-468 cells were treated with 10 μM dehydrocrenatidine for indicated time points, and cell extracts were analyzed by Western blot. DMSO was used as control. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    Dehydrocrenatidine inhibited IL-6 and IFN-induced STAT3 phosphorylation and their downstream gene expression. (A) Hela, HepG2, and HEK293T cells were cultured in Dulbecco’s modified Eagle’s medium with 0.2% FBS for 12 hours. Serum-starved cells were pretreated with DMSO or dehydrocrenatidine (10 μM) for 1 hour and stimulated by IL-6 (250 ng/ml) for 2 hours, and cell lysates were blotted by indicated antibodies. (B) Serum-starved Hela cells were incubated with DMSO or dehydrocrenatidine (10 μM) for 1 hour and treated with IFNγ (150 IU/ml) or (C) IFNα (5000 IU/ml) for 2 hours. Cells lysates were blotted by indicated antibodies. (D) Serum-starved Hela cells were incubated with DMSO or dehydrocrenatidine with indicated concentrations for 1 hour and stimulated with IFNα (5000 IU/ml) for 2 hours. Cell lysates were blotted by indicated antibodies. p-STAT1/STAT1 relative density was measured by Image J, and IC50 was calculated by SPSS software. (E) Hela and (F) HepG2 cells were serum-starved and pretreated with DMSO or dehydrocrenatidine (10 μM) for 1 hour and stimulated by IL-6 (250 ng/ml) for 4 hours. mRNA levels of socs3 were analyzed by real-time PCR. (G) Serum-starved Hela cells were pretreated with DMSO or dehydrocrenatidine (10 μM) for 1 hour and stimulated by IFNα (5000 IU/ml) for 4 hours, and irf1 mRNA levels were analyzed by real-time PCR. Data are mean ± S.D. of three independent experiments. ***P < 0.001, one-way analysis of variance. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

  • Fig. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    Dehydrocrenatidine inhibited overexpression of the JH1 domain of JAK1-, JAK2-, and TYK2-induced protein phosphorylation. (A) HEK293T cells transfected with JH1 domain of JAK1, JAK2, and TYK2 were treated with dehydrocrenatidine (15 μM) for 4 hours and blotted by indicated antibodies. (B) Serum-starved Hela cells were pretreated with DMSO, dehydrocrenatidine (15 μM), or lapatinib (10 μM) for 1 hour and stimulated with EGF (50 ng/ml) for 30 minutes, and cell lysates were Western blotted. (C) HEK293T cells overexpressing c-Src were incubated with dehydrocrenatidine (15 μM) or dasatinib (500 nM) for 4 hours. Cell lysates were analyzed by Western blot. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

  • Fig. 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 6.

    Dehydrocrenatidine induced apoptosis. (A) DU145 and (B) MDA-MB-468 cells were plated on coverslips. After 12 hours, medium was replaced and DMSO (a and c) or dehydrocrenatidine (10 μM) (b and d) was added. After 16 hours of treatment, cells were stained with Hoechst and visualized under a microscope (a and b, 40× magnification; c and d, 20× magnification). (C) DU145 and MDA-MB-468 cells were treated with DMSO or dehydrocrenatidine (10 μM) for 24 hours, double stained by annexin V and propidium iodide, and flow cytometry was performed. (D) DU145 and MDA-MB-468 cells were treated with dehydrocrenatidine (10 μM) for 24 or 48 hours. Cell lysates were analyzed by Western blot. DMSO was used as control. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

  • Fig. 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 7.

    Dehydrocrenatidine inhibited JAK2-JH1–induced STAT3 phosphorylation. (A) Recombined hSTAT3 protein and purified JAK2-JH1 kinase domain protein were used for kinase assay. Dehydrocrenatidine was applied at the following concentration series: 20, 40, 80, 100, or 200 μM. p-STAT3 levels were analyzed by Western blot. (B) Three independent kinase assays were performed. p-STAT3/STAT3 relative densities were quantified by Image J. Data represent mean ± S.D. of three independent experiments.

Additional Files

  • Figures
  • Data Supplement

    Files in this Data Supplement:

    • Supplemental Data -

      Supplemental Figure 1 - The structures of ranking top 5 molecules

      Supplemental Figure 2 - Western blot confirmation of activity of the top ranking molecules

      Supplemental Figure 3 - 1H-NMR spectrum for Dehydrocrenatidine

      Supplemental Figure 4 - MS for Dehydrocrenatidine

      Supplemental Figure 5 - HPLC for Dehydrocrenatidine

      Supplemental Figure 6 - Docking results between JAK1, JAK2, JAK3, TYK2 and Dehydrocrenatidine

      Supplemental Figure 7 - K562 cells were cultured in RMPI-1640 with 0.2% FBS for 12 hours...

      Supplemental Table 1 - The structures of JAK2 inhibitors

      Supplemental Method 1

      References

PreviousNext
Back to top

In this issue

Molecular Pharmacology: 87 (4)
Molecular Pharmacology
Vol. 87, Issue 4
1 Apr 2015
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Dehydrocrenatidine Is a Novel Janus Kinase Inhibitor
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Dehydrocrenatidine Is a Novel JAK Inhibitor

Jing Zhang, Ning Zhu, Yuping Du, Qifeng Bai, Xing Chen, Jing Nan, Xiaodong Qin, Xinxin Zhang, Jianwen Hou, Qin Wang and Jinbo Yang
Molecular Pharmacology April 1, 2015, 87 (4) 572-581; DOI: https://doi.org/10.1124/mol.114.095208

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

Dehydrocrenatidine Is a Novel JAK Inhibitor

Jing Zhang, Ning Zhu, Yuping Du, Qifeng Bai, Xing Chen, Jing Nan, Xiaodong Qin, Xinxin Zhang, Jianwen Hou, Qin Wang and Jinbo Yang
Molecular Pharmacology April 1, 2015, 87 (4) 572-581; DOI: https://doi.org/10.1124/mol.114.095208
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • P2X7 Positive Modulator Structure-Activity Relationship
  • Predicting Drug Interactions with ENT1 and ENT2
  • GABAAR Molecular Identity in Oligodendrocytes
Show more Articles

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics